CPRX Stock Summary and Trading Ideas (Catalyst Pharmaceuticals | NASDAQ:CPRX)

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Catalyst Pharmaceuticals trades on the NASDAQ stock market under the symbol CPRX.

As of January 29, 2026, CPRX stock price climbed to $24.58 with 858,084 million shares trading.

CPRX has a beta of 0.46, meaning it tends to be less sensitive to market movements. CPRX has a correlation of 0.07 to the broad based SPY ETF.

CPRX has a market cap of $3.02 billion. This is considered a Mid Cap stock.

Last quarter Catalyst Pharmaceuticals reported $148 million in Revenue and $.68 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.17.

In the last 3 years, CPRX traded as high as $26.58 and as low as $11.09.

The top ETF exchange traded funds that CPRX belongs to (by Net Assets): IJR, VTI, AVUV, IWM, XBI.

CPRX has underperformed the market in the last year with a return of +7.6%, while SPY returned +16.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CPRX shares. However, CPRX has outperformed the market in the last 3 month and 2 week periods, returning +15.1% and +6.1%, while SPY returned +1.3% and +0.5%, respectively. This indicates CPRX has been having a stronger performance recently.

CPRX support price is $23.61 and resistance is $24.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CPRX shares will trade within this expected range on the day.